Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Kadmon Corporation, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability

Early Phase 1

Completed

Conditions: Healthy Volunteers

First Posted Date: 2021-02-03

Last Posted Date: 2022-05-11

Lead Sponsor: Kadmon Corporation, LLC

Target Recruit Count: 30

Registration Number: NCT04735822

Locations: 🇬🇧
Quotient Sciences, Nottingham, England, United Kingdom

Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025

Phase 1

Completed

Conditions: Autoimmune Diseases
Fibrosis

Interventions: Drug: [14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose
Drug: [14C]-KD025 200 mg capsule
Drug: Belumosudil 200 mg tablet

First Posted Date: 2019-04-09

Last Posted Date: 2022-05-26

Lead Sponsor: Kadmon Corporation, LLC

Target Recruit Count: 5

Registration Number: NCT03907540

Locations: 🇬🇧
Quotient Sciences Ltd, Ruddington, Nottingham, United Kingdom

Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

Phase 1

Completed

Conditions: Drug-drug Interaction
Autoimmune Diseases
Fibrotic Disease

Interventions: Drug: Belumosudil
Drug: Itraconazole
Drug: Rabeprazole
Drug: Rifampicin
Drug: Omeprazole

First Posted Date: 2018-05-21

Last Posted Date: 2022-05-25

Lead Sponsor: Kadmon Corporation, LLC

Target Recruit Count: 73

Registration Number: NCT03530995

Locations: 🇬🇧
Quotient Sciences Ltd, Ruddington, Nottingham, United Kingdom

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Phase 1

Completed

Conditions: Polycystic Kidney, Autosomal Recessive

Interventions: Drug: Tesevatinib

First Posted Date: 2017-03-30

Last Posted Date: 2022-05-11

Lead Sponsor: Kadmon Corporation, LLC

Target Recruit Count: 10

Registration Number: NCT03096080

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

Phase 2

Completed

Conditions: Chronic Plaque Psoriasis

Interventions: Drug: Belumosudil
Drug: Placebo

First Posted Date: 2016-08-02

Last Posted Date: 2022-03-16

Lead Sponsor: Kadmon Corporation, LLC

Target Recruit Count: 110

Registration Number: NCT02852967

Locations: 🇺🇸
Alliance Dermatology and Mohs Center, Phoenix, Arizona, United States
🇺🇸
University of California, Irvine - Dermatology Clinical Research Center, Irvine, California, United States
🇺🇸
Dermatology Research Associates, Los Angeles, California, United States

and more 10 locations

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Phase 2

Completed

Conditions: Brain Tumor
Recurrent Glioblastoma
Glioblastoma

Interventions: Drug: Tesevatinib

First Posted Date: 2016-07-26

Last Posted Date: 2021-09-22

Lead Sponsor: Kadmon Corporation, LLC

Target Recruit Count: 40

Registration Number: NCT02844439

Locations: 🇺🇸
Center for Neurosciences, Tucson, Arizona, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
University of California, San Francisco (UCSF), San Francisco, California, United States

and more 8 locations

A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis

Phase 2

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Other: BSC
Drug: Belumosudil

First Posted Date: 2016-02-23

Last Posted Date: 2022-09-08

Lead Sponsor: Kadmon Corporation, LLC

Target Recruit Count: 76

Registration Number: NCT02688647

Locations: 🇺🇸
Pulmonary Associates, PA, Phoenix, Arizona, United States
🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸
UC Davis Medical Center, Division of Pulmonary/CC/SM, Sacramento, California, United States

and more 7 locations

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer
Leptomeningeal Metastases
Brain Metastases

Interventions: Drug: Tesevatinib

First Posted Date: 2015-11-26

Last Posted Date: 2022-03-16

Lead Sponsor: Kadmon Corporation, LLC

Target Recruit Count: 36

Registration Number: NCT02616393

Locations: 🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸
USC Norris Oncology/Hematology Newport Beach, Newport Beach, California, United States
🇺🇸
John Wayne Cancer Institute, Santa Monica, California, United States

and more 4 locations

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

Phase 2

Terminated

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions: Drug: tesevatinib

First Posted Date: 2015-11-26

Last Posted Date: 2022-05-25

Lead Sponsor: Kadmon Corporation, LLC

Target Recruit Count: 15

Registration Number: NCT02616055

Locations: 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 3 locations

Bioavailability of Belumosudil (KD025) in Healthy Male Subjects

Phase 1

Completed

Conditions: Bioavailability

Interventions: Drug: Belumosudil Tablet
Drug: Belumosudil Capsule

First Posted Date: 2015-09-23

Last Posted Date: 2022-05-25

Lead Sponsor: Kadmon Corporation, LLC

Target Recruit Count: 23

Registration Number: NCT02557139

Locations: 🇬🇧
Quotient Clinical Limited, Ruddington Nottingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy